close
close

Gilead Sciences (NASDAQ:GILD) stock rating reaffirmed by Oppenheimer


Gilead Sciences (NASDAQ:GILD – Get a Free Report)The stock’s “outperform” rating was adjusted by equity research analysts at Oppenheimer in a report issued Friday, Benzinga reports. They currently have a $105.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price target would suggest a potential upside of 57.28% from the stock’s current price.

A number of other research analysts have also weighed in on the company. Cantor Fitzgerald lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7. Royal Bank of Canada lowered their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14. Wells Fargo & Company lowered their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equalweight” rating on the stock in a report on Monday, March 4. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong buy” rating in a report on Tuesday, March 26. Finally, Mizuho lowered their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and an average price target of $84.71.

Read our latest research report on Gilead Sciences

Gilead Sciences is trading 0.9% higher

Shares of NASDAQ:GILD opened at $66.76 on Friday. The company’s 50-day moving average is $71.96 and its 200-day moving average is $76.56. Gilead Sciences has a 1-year low of $65.90 and a 1-year high of $87.86. The company has a market cap of $83.12 billion, a price-to-earnings ratio of 14.84, a price-to-earnings ratio of 0.91 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last reported its earnings results on Tuesday, February 6. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same period last year, the company earned $1.67 in earnings per share. The company’s quarterly revenue fell 3.7% year over year. On average, research analysts predict that Gilead Sciences will post earnings per share of 6.55 for the current fiscal year.

Insiders place their bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of stock in a transaction that occurred on Wednesday, February 28th. The stock sold at an average price of $73.18, for a total transaction of $146,360.00. Following the transaction, the insider now owns 100,936 shares in the company, valued at $7,386,496.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC’s website. 0.16% of the shares are currently owned by company insiders.

Hedge funds weigh on Gilead Sciences

Hedge funds have recently bought and sold shares of the company. Capital World Investors increased its position in shares of Gilead Sciences by 2.0% in the fourth quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock valued at $6,753,350,000 after acquiring an additional 1,642,736 shares in the last quarter. Capital Research Global Investors increased its position in shares of Gilead Sciences by 3.0% in the fourth quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock valued at $4,832,824,000 after acquiring an additional 1,743,418 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Gilead Sciences by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after acquiring an additional 2,350,550 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after acquiring an additional 13,764,169 shares in the last quarter. Finally, Morgan Stanley increased its position in shares of Gilead Sciences by 11.5% in the fourth quarter. Morgan Stanley now owns 17,196,950 shares of the biopharmaceutical company’s stock valued at $1,476,358,000 after acquiring an additional 1,780,489 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s shares.

Gilead Sciences Company Profile

(Get a free report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops and commercializes medicines addressing unmet medical needs in the United States, Europe and internationally. The company provides products from Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs and Atripla for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy and Viread for the treatment of viral hepatitis.

Read further

Analyst recommendations for Gilead Sciences (NASDAQ:GILD)



Get daily news and reviews for Gilead Sciences – Enter your email address below to receive a concise daily digest of the latest news and analyst ratings for Gilead Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.